VAV00039 is a first-in-human (FiH) study to assess the safety and immunogenicity (in adult participants aged 60-75 years) after a single injection of different dose formulations of an RSV/hMPV vaccine candidate and RSV vaccine.

The purpose of this study is to test if an adjuvant (called SPA09) can improve the strength and function of an mRNA vaccine, without giving unwanted effects. This study will use an experimental mRNA vaccine designed to prevent lung disease caused by two viruses, named RSV and hMPV. Healthy adults, 60 to 75 years of age will participate in this Phase 1, randomized, modified double-blind, multi-center, parallel group, multi-arm study. Each participant will remain in the study for approximately 6 months.

We are currently recruiting participants for a medical research study that is testing a new investigational vaccine to protect against disease caused by the respiratory syncytial virus (RSV) and human metapneumovirus  (hMPV).